In the News
MilliporeSigma to Open China’s First Mobius® Single-use Manufacturing Facility in Wuxi
- MilliporeSigma’s first single-use manufacturing facility to support biopharma industry development in China
- Flexible and customized solutions to accelerate drug development in China
MilliporeSigma, the vibrant science and technology company, today announced the establishment of its first Mobius® Single-use Manufacturing Facility in China. Located in Wuxi, the facility will provide flexible and customized single-use solutions to support local customers in accelerating drug development and manufacturing. The facility is undergoing qualification with product manufacturing and is expected to be operational by Q1 2019.
“We have seen a rapidly growing demand for biologics in China in recent years, with a strong focus on improving the manufacturing process every step of the way,” said Udit Batra, Member of the Executive Board, Merck KGaA, Darmstadt, Germany, CEO MilliporeSigma. “With our new single-use manufacturing facility, we will help customers by providing the efficiency and flexibility they need in the development, scale-up and manufacturing phases.”
Staffed with local employees with global expertise, the facility will produce Mobius® Select assemblies, a key offering as part of the Mobius® MyWay program, with the same quality, manufacturing systems and standards used at MilliporeSigma’s Single-use Center of Excellence in Danvers, Massachusetts, USA. The new facility includes a dedicated clean room space for single-use product assembly.
MilliporeSigma’s Mobius® MyWay program provides biopharmaceutical manufacturers the flexibility to configure single-use assemblies based on their unique processing needs, while also offering enhanced supply security and speed-to-market. Using MilliporeSigma’s Mobius® Select offering, manufacturers can reduce the traditional lead time of more than 14 weeks to six weeks, and to as little as 24 hours with MilliporeSigma’s Mobius® Stock.“Single-use is a very flexible technology that allows the development and production of products in a wide range of sizes and for a different variety of diseases,” said Peter Shen, vice president of WuXi Biologics. “This flexibility coupled with smaller investment in early-stage fixed assets result in higher production efficiency and lower gross costs. Mobius® Select provides design flexibility and the speed needed to meet our unique processing requirements.”
Follow MilliporeSigma on Twitter @EMDgroup